A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

@article{Vincenti2010API,
  title={A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).},
  author={Flavio G. Vincenti and Bernard Charpentier and Yves F Ch Vanrenterghem and Lionel P E Rostaing and Barbara Bresnahan and Parth Darji and Pablo Massari and Guillermo Antonio Mondrag{\'o}n-Ram{\'i}rez and Mamta Agarwal and Gregory Di Russo and Chia-shu Lin and Pushkal P Garg and Christian P Larsen},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2010},
  volume={10 3},
  pages={535-46}
}
Belatacept, a costimulation blocker, may preserve renal function and improve long-term outcomes versus calcineurin inhibitors in kidney transplantation. This Phase III study (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) assessed a more intensive (MI) or less intensive (LI) regimen of belatacept versus cyclosporine in adults receiving a kidney transplant from living or standard criteria deceased donors. The co-primary endpoints at 12 months were… CONTINUE READING
Highly Influential
This paper has highly influenced 18 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 280 extracted citations

Similar Papers

Loading similar papers…